NewsBenzingaImmutep informa datos alentadores de supervivencia del ensayo de fase II EFTISARC-NEO en sarcoma; Efti + KEYTRUDA + radioterapia muestra una DFS a 12 meses del 81,1 %, una LRFS del 94,1 % y una DMFS del 86,2 % en 38 pacientes Immutep informa datos alentadores de supervivencia del ensayo de fase II EFTISARC-NEO en sarcoma; Efti + KEYTRUDA + radioterapia muestra una DFS a 12 meses del 81,1 %, una LRFS del 94,1 % y una DMFS del 86,2 % en 38 pacientes Benzinga 2026.11.10 23:03 (GMT+0) Open on Benzinga Other news Ramp in Talks to Raise at Least $1 Billion at Valuation of Up to $75 Billion How Everyday Investors Are Playing the Nvidia Drama Curve: Fee Conversion Contract Loses $38.2K in Attack, Disabled With Replacement Planned Alvotech (ALVO) Presents at UBS Global Biopharma Conference 2026 Transcript Nvidia Tops Sales Forecast After Huang's Resignation Bill Gates Has Earned $2.6 Billion in Dividends From a Landfill Stock the EPA Keeps Citing for Methane Leaks, and a Filing Shows He Just Bought 3.7M More Shares
Bill Gates Has Earned $2.6 Billion in Dividends From a Landfill Stock the EPA Keeps Citing for Methane Leaks, and a Filing Shows He Just Bought 3.7M More Shares